Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of tofacitinib citrate in the treatment of Takayasu arteritis

A technology of tofacitinib and Takayasu, applied in the field of application of tofacitinib citrate in the treatment of Takayasu, which can solve the problems of unsatisfactory long-term effect, high cost and high risk

Active Publication Date: 2019-12-27
JIANGSU WANBANG BIOPHARMLS
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

There are few clinical reports on the use of this type of drug. Although it has a certain effect in the treatment of patients with recurrent and refractory Takayasu arteritis, the application effect in mild to moderate patients is not clear.
In addition, there are methods such as interventional therapy and surgical treatment, but they also have disadvantages such as high cost, high risk, and unsatisfactory long-term effect.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0012] Example 1 Application of Tofacitinib Citrate in the Treatment of Takayasu Arteritis

[0013] 1. Materials and methods

[0014] 1.1 Experimental objects and grouping

[0015] Twenty-six TA patients (diagnostic criteria refer to the American College of Rheumatology in 2009: ① age of onset ≤ 40 years old; ② intermittent movement disorder of limbs; ③ weakened brachial artery pulse; ④ systolic pressure difference of both upper extremities > 10 mmHg; Aortic murmur; ⑥Arterial angiography shows stenosis or occlusion of the aorta and its branches or the proximal large arteries of the extremities, and those caused by arteriosclerosis, fibromuscular dysplasia, etc. are excluded. Note: digital subtraction angiography or angiography Vascular stenosis or dilation as the final diagnostic criteria.) Randomly divided into treatment group 16 cases and control group 10 cases, two groups in gender, age, condition and other general clinical data, the difference was not significant ( p >0....

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application method of tofacitinib citrate in the medical field. The specific implementation method is that drug administration per oral is carried out to treat the multiple arteritis. Clinical experimental study indicates that the tofacitinib citrate can be given to a multiple arteritis patient to obviously relieve symptoms including limb intermittent dyskinesia, aorta and branch or limb proximal aortic stenosis or occlusion and the like, laboratory index C reactive protein is obviously lowered, the relapse risk of diseases can be lowered, and the living quality of the patient is improved.

Description

technical field [0001] The invention relates to an application of tofacitinib citrate in medicine for treating Takayasu arteritis. Background technique [0002] Takayasuarteritis (TA), also known as Kawasaki disease, is a chronic inflammatory disease of unknown etiology, mainly involving the aorta and its main branches, and the pulmonary artery can also be involved. The disease is more common in women of childbearing age, but also in men and other age groups. Clinical manifestations mainly include nonspecific systemic symptoms and characteristic ischemic symptoms. Systemic symptoms mainly include fever, arthralgia, night sweats, weight loss, etc.; ischemic symptoms are mainly related to the scope and severity of blood vessels involved, including intermittent claudication, weak pulse, angina, vision loss, and stroke. The disease is a worldwide disease, and the incidence rate in East Asia, South Asia, and Latin America is higher than other regions, and the annual incidence r...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/519A61P9/14A61P9/10A61P27/10
CPCA61K31/519
Inventor 王伟高雪芹李惠珠乔德水
Owner JIANGSU WANBANG BIOPHARMLS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products